ClinicalTrials.gg
CompletedNCT02494596Updated Nov 10, 2015Results posted

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

A Phase 1 interventional study of Capecitabine and RhuMab 2C4 in Solid Tumor, sponsored by Hoffmann-La Roche. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-10.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4(Perjeta) and capecitabine (Xeloda) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. Participants will be enrolled and evaluated for dose-limiting toxicities (DLTs) in escalating-dose cohorts in order to determine the maximum tolerated dose (MTD).

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults at least 18 years of age
  • Easter Cooperative Oncology Group () performance status of 0 or 1
  • at least 12 weeks
  • Locally advanced or solid tumor with at least 1 , which has progressed during/after standard therapy
  • Human epidermal growth factor receptor 2 ()-negative among participants with breast cancer
  • Negative pregnancy test or use of an adequate method among women of
  • Adequate hematologic, hepatic, and renal function

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of central nervous system (CNS)
  • Prior chemotherapy, radiotherapy, or immunotherapy within 4 weeks, or hormone therapy within 2 weeks of study Day 1
  • History of palmar plantar syndrome Grade 2 or worse, or any unresolved residual chemotherapy effects
  • Prior -active agents, continuous intravenous (IV) 5-fluorouracil, capecitabine, or other fluoropyrimidine
  • Any agent within 28 days of study start
  • Prior cumulative doxorubicin dose greater than (>) 360 mg/m\^2 or equivalent
  • Significant cardiovascular disease
  • Active/uncontrolled concurrent illness or infection-
  • Major surgery or trauma within 4 weeks of study Day 1
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)

    Participants will receive a single 1000-mg/m\^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.

    Drug: Capecitabine · Drug: RhuMab 2C4

  • Experimental
    RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)

    Participants will receive a single 1250-mg/m\^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.

    Drug: Capecitabine · Drug: RhuMab 2C4

  • Experimental
    RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)

    Participants will receive a single 825-mg/m\^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.

    Drug: Capecitabine · Drug: RhuMab 2C4

Interventions

  • Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

    Also known as: Xeloda

  • Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

    Also known as: Omnitarg

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine

    MTD was defined as the highest tolerated dose combination of capecitabine (825 mg, 1000 mg or 1250 mg) and pertuzumab, without causing Dose Limiting Toxicities (DLTs). DLTs were defined as follows: 1) Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT. MTD was measured in mg/m\^2.

    Time frame: Cycle 1 (3 Weeks)

Secondary outcomes

  1. Percentage of Participants With DLTs

    DLTs were defined as follows: 1)Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT.

    Time frame: Cycle 1 (3 Weeks)

  2. Plasma Half-Life (t1/2) of Pertuzumab

    The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity. t1/2 was measured in days.

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and Predose on Days 8, 15 and 22

  3. Maximum Plasma Concentration (Cmax) of Pertuzumab

    Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and was measured as nanograms per milliliter (ng/mL).

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22

  4. Time to Maximum Plasma Concentration (Tmax) of Pertuzumab

    Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. Tmax was measured in days.

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22

  5. Area Under the Concentration Curve From Time Zero to Last Measurement (AUC 0-last) of Pertuzumab

    The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC was measured as ng\*day/mL.

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22

  6. AUC From Time Zero to Infinity (AUC 0-infinity) of Pertuzumab

    The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as nanograms times days per milliliter (ng\*day/mL).

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22

  7. Apparent Volume of Distribution of Pertuzumab

    The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Vss was measured in mL

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22

  8. Apparent Total Clearance of Pertuzumab

    Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

    Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22

  9. Plasma Half-Life of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab

    Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). The biological half-life or terminal half-life is the time in days it takes for it to lose half of its pharmacologic activity.

    Time frame: Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose

  10. Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab

    Capecitabine is an oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety 5-FU in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-DFCR, 5'-DFUR, and FBAL. Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL).

    Time frame: Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose

  11. Time to Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab

    Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination.

    Time frame: Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose

07

Results

Posted Sep 30, 2015

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine 825 Plus (+) Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
Started577
Completed226
Not completed351
Withdrew: Insufficient therapeutic response331
Withdrew: Adverse event010
Withdrew: Refused treatment010

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine

MTD was defined as the highest tolerated dose combination of capecitabine (825 mg, 1000 mg or 1250 mg) and pertuzumab, without causing Dose Limiting Toxicities (DLTs). DLTs were defined as follows: 1) Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT. MTD was measured in mg/m\^2.

Time frame:
Cycle 1 (3 Weeks)
Reported as:
Number · mg/m^2
Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine
mg/m^2Capecitabine + Pertuzumab
Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine1250
SecondaryPercentage of Participants With DLTs

DLTs were defined as follows: 1)Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT.

Time frame:
Cycle 1 (3 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With DLTs
percentage of participantsCapecitabine 825 Plus (+) Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
Percentage of Participants With DLTs0.00.00.0
SecondaryPlasma Half-Life (t1/2) of Pertuzumab

The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity. t1/2 was measured in days.

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and Predose on Days 8, 15 and 22
Reported as:
Mean · days
Plasma Half-Life (t1/2) of Pertuzumab
daysCapecitabine + Pertuzumab
Plasma Half-Life (t1/2) of Pertuzumab14.6 ± 41.0
SecondaryMaximum Plasma Concentration (Cmax) of Pertuzumab

Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and was measured as nanograms per milliliter (ng/mL).

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Pertuzumab
ng/mLCapecitabine + Pertuzumab
Maximum Plasma Concentration (Cmax) of Pertuzumab355111 ± 59051
SecondaryTime to Maximum Plasma Concentration (Tmax) of Pertuzumab

Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. Tmax was measured in days.

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Reported as:
Mean · days
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
daysCapecitabine + Pertuzumab
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab0.137 ± 0.076
SecondaryArea Under the Concentration Curve From Time Zero to Last Measurement (AUC 0-last) of Pertuzumab

The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC was measured as ng\*day/mL.

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Reported as:
Mean · ng*day/mL
Area Under the Concentration Curve From Time Zero to Last Measurement (AUC 0-last) of Pertuzumab
ng*day/mLCapecitabine + Pertuzumab
Area Under the Concentration Curve From Time Zero to Last Measurement (AUC 0-last) of Pertuzumab2742561 ± 743598
SecondaryAUC From Time Zero to Infinity (AUC 0-infinity) of Pertuzumab

The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as nanograms times days per milliliter (ng\*day/mL).

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Reported as:
Mean · ng*day/mL
AUC From Time Zero to Infinity (AUC 0-infinity) of Pertuzumab
ng*day/mLCapecitabine + Pertuzumab
AUC From Time Zero to Infinity (AUC 0-infinity) of Pertuzumab4096501 ± 1282130
SecondaryApparent Volume of Distribution of Pertuzumab

The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Vss was measured in mL

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Reported as:
Mean · mL
Apparent Volume of Distribution of Pertuzumab
mLCapecitabine + Pertuzumab
Apparent Volume of Distribution of Pertuzumab5202 ± 1007
SecondaryApparent Total Clearance of Pertuzumab

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

Time frame:
Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Reported as:
Mean · mL/day
Apparent Total Clearance of Pertuzumab
mL/dayCapecitabine + Pertuzumab
Apparent Total Clearance of Pertuzumab283.0 ± 98.0
SecondaryPlasma Half-Life of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab

Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). The biological half-life or terminal half-life is the time in days it takes for it to lose half of its pharmacologic activity.

Time frame:
Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose
Reported as:
Mean · hours
Plasma Half-Life of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab
hoursCapecitabine 825 + Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
Capecitabine Alone 5'-DFCR0.89 ± 0.270.82 ± 0.280.82 ± 0.23
Capecitabine Alone 5'-DFUR0.75 ± 0.260.76 ± 0.230.66 ± 0.09
Capecitabine Alone 5-FU0.67 ± 0.220.64 ± 0.130.70 ± 0.16
Capecitabine Alone Capecitabine0.54 ± 0.190.40 ± 0.100.36 ± 0.11
Capecitabine Alone FBAL2.54 ± 0.302.69 ± 0.393.08 ± 0.78
Capecitabine + Pertuzumab 5'-DFCR0.78 ± 0.380.76 ± 0.180.75 ± 0.14
Capecitabine + Pertuzumab 5'-DFUR0.62 ± 0.130.73 ± 0.210.79 ± 0.28
Capecitabine + Pertuzumab 5-FU0.73 ± 0.400.67 ± 0.140.80 ± 0.35
Capecitabine + Pertuzumab Capecitabine0.42 ± 0.140.62 ± 0.280.54 ± 0.28
Capecitabine + Pertuzumab FBAL2.59 ± 0.642.58 ± 0.572.81 ± 0.44
SecondaryMaximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab

Capecitabine is an oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety 5-FU in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-DFCR, 5'-DFUR, and FBAL. Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL).

Time frame:
Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab
ng/mLCapecitabine 825 + Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
Capecitabine Alone 5'-DFCR4508 ± 23177687 ± 14438647 ± 3254
Capecitabine Alone 5'-DFUR5274 ± 18327657 ± 270810311 ± 3323
Capecitabine Alone 5-FU201 ± 94355 ± 119369 ± 107
Capecitabine Alone Capecitabine4802 ± 31599112 ± 61897543 ± 2944
Capecitabine Alone FBAL3214 ± 3963963 ± 9475290 ± 576
Capecitabine + Pertuzumab 5'-DFCR4909 ± 25183917 ± 14116569 ± 2827
Capecitabine + Pertuzumab 5'-DFUR5736 ± 18314103 ± 15958683 ± 4142
Capecitabine + Pertuzumab 5-FU219 ± 106187 ± 92345 ± 214
Capecitabine + Pertuzumab Capecitabine8060 ± 48003367 ± 17414731 ± 3198
Capecitabine + Pertuzumab FBAL3674 ± 11213498 ± 8095136 ± 843
SecondaryTime to Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab

Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination.

Time frame:
Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose
Reported as:
Mean · hours
Time to Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab
hoursCapecitabine 825 + Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
Capecitabine Alone 5'-DFCR1.3 ± 0.660.82 ± 0.261.05 ± 0.51
Capecitabine Alone 5'-DFUR1.3 ± 0.660.76 ± 0.491.05 ± 0.51
Capecitabine Alone 5-FU1.3 ± 0.660.64 ± 0.491.05 ± 0.51
Capecitabine Alone Capecitabine1.2 ± 0.750.4 ± 0.280.77 ± 0.35
Capecitabine Alone FBAL2.4 ± 0.552.69 ± 0.412.21 ± 0.40
Capecitabine + Pertuzumab 5'-DFCR0.9 ± 0.651.42 ± 0.661.86 ± 1.32
Capecitabine + Pertuzumab 5'-DFUR1.0 ± 0.612.0 ± 1.101.86 ± 1.32
Capecitabine + Pertuzumab 5-FU0.9 ± 0.651.84 ± 1.171.93 ± 1.24
Capecitabine + Pertuzumab Capecitabine0.7 ± 0.281.17 ± 0.401.15 ± 0.62
Capecitabine + Pertuzumab FBAL2.6 ± 0.903.16 ± 1.172.50 ± 1.39

Adverse events

Collected over Adverse events were recorded continuously from Day -7 until 4 weeks after the final visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine 825 + Pertuzumab 1050—0/5 (0%)5/5 (100%)
Capecitabine 1000 + Pertuzumab 1050—1/6 (16.7%)6/6 (100%)
Capecitabine 1250 + Pertuzumab 1050—1/7 (14.3%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventCapecitabine 825 + Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
Intestinal ObstructionGastrointestinal disorders0/51/60/7
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/50/61/7
Most frequent other events
Showing 10 of 64
Most frequent other events
EventCapecitabine 825 + Pertuzumab 1050Capecitabine 1000 + Pertuzumab 1050Capecitabine 1250 + Pertuzumab 1050
DiarrhoeaGastrointestinal disorders3/53/67/7
NauseaGastrointestinal disorders4/54/64/7
AstheniaGeneral disorders1/53/64/7
Mucosal inflammationGeneral disorders0/52/64/7
AnorexiaMetabolism and nutrition disorders2/53/64/7
Keratoconjunctivitis siccaEye disorders0/50/64/7
VomitingGastrointestinal disorders2/53/62/7
ConstipationGastrointestinal disorders0/50/63/7
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/50/63/7
InsomniaPsychiatric disorders0/50/63/7

Baseline characteristics

The Intent-To-Treat (ITT) Population included all participants who received any amount of the study medication. The baseline analysis population represents participants from all three cohorts.

Age, Continuous
Age, Continuous(years)Capecitabine + Pertuzumab
Mean60.9 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine + Pertuzumab
Female11
Male7
08

Study locations

2 sites
  • Barcelona, 08036, Spain
  • Manchester, M20 4BX, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 10 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2015
First posted
Jul 10, 2015
Start
Jan 2004
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Results first posted
Sep 30, 2015
Last update
Nov 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02494596
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 10, 2015
Start date
Jan 2004
Primary completion
Sep 2005
Completion
Sep 2005
Results posted
Sep 30, 2015
Last update
Nov 10, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion